ライフサイエンスコーパス: cardiac transplantation

1 rse clinical events (all-cause mortality and cardiac transplantation).

2 ere were 52 deaths, and 7 patients underwent cardiac transplantation.

3 omposite of HF death, HF hospitalization, or cardiac transplantation.

4 eting in murine recipients in the context of cardiac transplantation.

5 ion, ventricular assist device insertion, or cardiac transplantation.

6 he targeting of P2X7R a potential therapy in cardiac transplantation.

7 CM) remain at high risk of death or need for cardiac transplantation.

8 acting survival in the first 12 months after cardiac transplantation.

9 ticles on the volume-outcome relationship in cardiac transplantation.

10 s the leading cause of early death following cardiac transplantation.

11 the time of ISDC-therapy in a mouse model of cardiac transplantation.

12 ia, mandating single-ventricle palliation or cardiac transplantation.

13 roved cancer-free and overall survival after cardiac transplantation.

14 red from ischemic cardiomyopathy patients at cardiac transplantation.

15 tudy of ECG findings in potential donors for cardiac transplantation.

16 performed in a center and the outcome after cardiac transplantation.

17 failure in addition to device placement and cardiac transplantation.

18 ic manipulations for tolerance induction for cardiac transplantation.

19 e, end stage heart failure, and the need for cardiac transplantation.

20 tion therapy in those who are ineligible for cardiac transplantation.

21 cular assist devices or potential donors for cardiac transplantation.

22 were collected from patients at the time of cardiac transplantation.

23 rdioprotection in a rat model of heterotopic cardiac transplantation.

24 rejection in a murine model of vascularized cardiac transplantation.

25 e not anastomosed to recipient lymphatics in cardiac transplantation.

26 after an ischemic time relevant to clinical cardiac transplantation.

27 e option for improving outcomes in pediatric cardiac transplantation.

28 t common cause of short-term mortality after cardiac transplantation.

29 f the TEA alone patients underwent an urgent cardiac transplantation.

30 8 eligible patients, nine patients underwent cardiac transplantation.

31 ence of viral endomyocardial infection after cardiac transplantation.

32 oronary artery 3.61 +/- 3.04 years following cardiac transplantation.

33 uality of life and lifespan of patients with cardiac transplantation.

34 ft dysfunction, and a higher mortality after cardiac transplantation.

35 heart failure severity and risk of death or cardiac transplantation.

36 months, the patient underwent a heterotopic cardiac transplantation.

37 mposite end point was all-cause mortality or cardiac transplantation.

38 of recipient RAAS polymorphisms in pediatric cardiac transplantation.

39 t ideal body weight <140%-before listing for cardiac transplantation.

40 apeutic target for allograft rejection after cardiac transplantation.

41 e, ejection fraction 18 +/- 8%) referred for cardiac transplantation.

42 ilure, GRK5-Leu41 protected against death or cardiac transplantation.

43 limiting factor in the long-term success of cardiac transplantation.

44 m explanted hearts of patients who underwent cardiac transplantation.

45 tive treatment, such as revascularization or cardiac transplantation.

46 ium iodide symporter (hNIS) gene transfer in cardiac transplantation.

47 ed with HCV transmission following renal and cardiac transplantation.

48 (LVH) and diastolic dysfunction occur after cardiac transplantation.

49 r of who will require permanent pacing after cardiac transplantation.

50 endent heart failure patients ineligible for cardiac transplantation.

51 does not differ between men and women after cardiac transplantation.

52 rtery lumen loss during the first year after cardiac transplantation.

53 t BNP interacts with the immune system after cardiac transplantation.

54 sufficiently while on therapy to qualify for cardiac transplantation.

55 ing and vessel remodeling, occur early after cardiac transplantation.

56 major cause of morbidity and mortality after cardiac transplantation.

57 onary lumen loss between years 1 and 2 after cardiac transplantation.

58 f myocardial recovery in patients bridged to cardiac transplantation.

59 Some patients may ultimately require cardiac transplantation.

60 diac-related hospitalization, or listing for cardiac transplantation.

61 opsy in the management of patients following cardiac transplantation.

62 ure (HF) patients and their implications for cardiac transplantation.

63 nt of death, hospitalization, or listing for cardiac transplantation.

64 , single ventricle physiology, and following cardiac transplantation.

65 ffect of donor HCV positivity on survival in cardiac transplantation.

66 8%) with postpartum cardiomyopathy underwent cardiac transplantation.

67 5+ regulatory T cells either before or after cardiac transplantation.

68 nificant increases even up to 10 years after cardiac transplantation.

69 laxis against acute cellular rejection after cardiac transplantation.

70 sist devices (VADs) are important bridges to cardiac transplantation.

71 funding source to be considered eligible for cardiac transplantation.

72 monly used in the evaluation of patients for cardiac transplantation.

73 is the major cause of late graft failure in cardiac transplantation.

74 cause mortality, with censoring for interval cardiac transplantation.

75 ns for all cardiac operations in addition to cardiac transplantation.

76 biventricular failure and are candidates for cardiac transplantation.

77 t failure and influence clinical listing for cardiac transplantation.

78 in allograft rejection in a murine model of cardiac transplantation.

79 rom 10 patients with end-stage HF undergoing cardiac transplantation.

80 ion of bone loss during the first year after cardiac transplantation.

81 injury and graft coronary artery disease in cardiac transplantation.

82 tic parameters that determine the outcome of cardiac transplantation.

83 for the prevention of bone loss early after cardiac transplantation.

84 PCI) and the predictors for restenosis after cardiac transplantation.

85 n-associated renal toxicity in recipients of cardiac transplantation.

86 essential in the progression of the field of cardiac transplantation.

87 ulatory death (DCD) to expand donor pool for cardiac transplantation.

88 s explored risk factors for interim death or cardiac transplantation.

89 ents have died and 3 LQT3 patients underwent cardiac transplantation.

90 , ventricular assist device implantation, or cardiac transplantation.

91 RIP3) mice to B6.C-H-2 (H2-Ab1; bm12) mouse cardiac transplantation.

92 ) is a major cause for late graft loss after cardiac transplantation.

93 cardiac arrest in patients with a history of cardiac transplantation.

94 oglobin is an enhancer of inflammation after cardiac transplantation.

95 ssist device (LVAD) placement as a bridge to cardiac transplantation.

96 e and function during tolerization in murine cardiac transplantation.

97 a growing problem in the field of pediatric cardiac transplantation.

98 ortant factor for morbidity and mortality in cardiac transplantation.

99 developed severe heart failure and underwent cardiac transplantation.

100 HC-mismatched models of allogeneic islet and cardiac transplantation.

101 LA) is a major risk factor for graft loss in cardiac transplantation.

102 tion is the major obstacle to survival after cardiac transplantation.

103 ded time to the combined outcome of death or cardiac transplantation.

104 The primary outcome was death or cardiac transplantation 12 months after randomization.

105 able cardioverter-defibrillator; 1 underwent cardiac transplantation; 2 had a resuscitated cardiac ar

106 ve implantation of a heart failure device or cardiac transplantation (22% risk reduction, P=0.07).

107 of 12.2 years, 76 (29.1%) died, 5 (1.9%) had cardiac transplantation, 5 (1.9%) had Fontan revision, a

108 survival was 69%; 42 patients (84%) received cardiac transplantation, 5 patients (10%) were weaned, a

109 omly assigned 602 patients who had undergone cardiac transplantation 6 months to 5 years previously t

110 For the first time since cardiac transplantation, a therapy is being developed to

111 sk of death, hospitalization, or listing for cardiac transplantation (adjusted hazard ratio, 63.6; P

112 defibrillator, ventricular assist device, or cardiac transplantation), adjusting for clinical and ech

113 to review the clinical course and outcome of cardiac transplantation after a failed Glenn or Fontan p

114 s to strongly predict all-cause mortality or cardiac transplantation after adjustment for traditional

115 points included cardiovascular mortality or cardiac transplantation; an arrhythmic composite of SCD

116 al rejection (HR) episodes occur early after cardiac transplantation and are associated with hemodyna

117 to the Index for Mortality Prediction After Cardiac Transplantation and Donor Risk Index score using

118 ial biopsy has defined rejection in clinical cardiac transplantation and established a threshold for

119 Two patients required cardiac transplantation and four died of cardiac failure

120 sy has defined the diagnosis of rejection in cardiac transplantation and has historically been a vita

121 This was true in renal and cardiac transplantation and in recipients with peak vira

122 nt, hyperlipidemia remains problematic after cardiac transplantation and is associated with the devel

123 ctory to conventional pharmacologic therapy, cardiac transplantation and mechanical circulatory suppo

124 tion for one-year postoperative mortality or cardiac transplantation and prolonged length of hospital

125 ill summarize the current state of pediatric cardiac transplantation and review recent advances leadi

126 Cardiac transplantation and sudden death were more preva

127 ts into the mechanisms of inflammation after cardiac transplantation and suggest that, in contrast to

128 icial heart improved the rate of survival to cardiac transplantation and survival after transplantati

129 with lumen loss during the first year after cardiac transplantation and that cytomegalovirus antibod

130 replace damaged cardiac tissue is limited to cardiac transplantation and thus many patients suffer pr

131 devices as a strategy to bridge patients to cardiac transplantation and, more recently, as a form of

132 ibers, 10-hr heart cold storage, heterotopic cardiac transplantation, and 24-hr reperfusion result in

133 se event-free survival from all-cause death, cardiac transplantation, and cardiac arrest (log-rank P=

134 were absence of sinus rhythm at enrollment, cardiac transplantation, and contraindications to colchi

135 zation, ventricular assist device placement, cardiac transplantation, and death.

136 n=23), normal human valves (n=20) removed at cardiac transplantation, and degenerative mitral valve l

137 Death, cardiac transplantation, and HF hospitalization were tra

138 All-cause mortality, cardiac transplantation, and HF hospitalization were tra

139 h advanced HF whose only previous option was cardiac transplantation, and it is now a realistic optio

140 events (all-cause mortality, cardiac death, cardiac transplantation, and MI) or major adverse cardio

141 The primary end point was death or cardiac transplantation, and secondary end points includ

142 Acute kidney injury is highly frequent after cardiac transplantation, and the stage of AKI is associa

143 h renal disease, children who have undergone cardiac transplantation, and those with aortic valve dis

144 phism, followed to the end point of death or cardiac transplantation, and transplant-free survival co

145 ly in childhood or adolescence or undergoing cardiac transplantation are affected by cardiomyopathies

146 discovered that inflammatory responses after cardiac transplantation are initiated through ferroptoti

147 sequences of acute kidney injury (AKI) after cardiac transplantation are scarce.

148 The causes of endothelial dysfunction after cardiac transplantation are unknown.

149 graft injury in the pre-engraftment phase of cardiac transplantation are warranted.

150 e report an adolescent patient who underwent cardiac transplantation as a result of restrictive cardi

151 t of two recipient lists as a way to provide cardiac transplantation as an option to recipients who w

152 sure in 6 groups of animals (rat heterotopic cardiac transplantation) as follows: tobacco-naive allog

153 tant in the management of patients following cardiac transplantation, as non-invasive techniques are

154 lude destination therapy and alternatives to cardiac transplantation, as the supply of organs continu

155 Newly evaluated patients for cardiac transplantation at an academic medical center ge

156 e heart failure in two sisters who underwent cardiac transplantation at three years of age.

157 arterial disease after total allomismatched cardiac transplantation (BALB/c donor heart and B6 recip

158 HO-1-derived CO prevents IRI associated with cardiac transplantation based on its antiapoptotic actio

159 re 2 late deaths because of RV failure and 1 cardiac transplantation because of progressive RV dysfun

160 ompatibility complex class II allomismatched cardiac transplantation (bm12 donor heart and B6 recipie

161 After cardiac transplantation, both cell types showed drastic

162 lished surgical therapy for heart failure is cardiac transplantation, but its impact is limited due t

163 has examined this relationship in pediatric cardiac transplantation, but low-volume adult heart tran

164 Anti-ICAM-1 antibodies are produced after cardiac transplantation, but not to polymorphic residues

165 Progression of heart failure can lead to cardiac transplantation, but when patients are ineligibl

166 associated with cardiovascular mortality or cardiac transplantation (by fibrosis presence: HR, 3.22

167 The individual risk of mortality or cardiac transplantation calculation produced by our deep

168 Cardiac transplantation can be performed successfully in

169 rgoing right heart catheterization to assess cardiac transplantation candidacy (N=141).

170 raft Vasculopathy Using Rituximab Therapy in Cardiac Transplantation [Clinical Trials in Organ Transp

171 en achieved, primary graft dysfunction after cardiac transplantation continues to be an important cau

172 remained stable during the second year after cardiac transplantation, despite a significant increase

173 Depletion of recipient cDCs after cardiac transplantation drastically decreased presentati

174 This demonstrates that cardiac transplantation followed by ASCT is feasible in

175 management of an infant who had heterotopic cardiac transplantation for advanced cardiomyopathy with

176 Cardiac transplantation for amyloid patients with extend

177 with LQTS after birth, ultimately requiring cardiac transplantation for control of ventricular tachy

178 dentified in the first proband who underwent cardiac transplantation for diastolic heart failure, her

179 evaluated adults who underwent single-organ, cardiac transplantation from 1994 to 2009 with a diagnos

180 records of all adult patients who underwent cardiac transplantation from January 2009 to February 20

181 records of all adult patients who underwent cardiac transplantation from January 2009 to February 20

182 After cardiac transplantation, graft damage occurs secondary t

183 also discuss how the funding requirement for cardiac transplantation has been addressed by the federa

184 The role for LVADs as a bridge to cardiac transplantation has been established, but data s

185 Improvements in early mortality after cardiac transplantation have occurred consistently over

186 ure death, heart failure hospitalization, or cardiac transplantation (hazard ratio, 2.70; 95% CI, 1.3

187 dary outcomes of cardiovascular mortality or cardiac transplantation (hazard ratio, 3.35; 95% CI, 1.7

188 use, lifesaving cardiovascular intervention (cardiac transplantation, implantation of a ventricular a

189 come occurred in 55, with death in 24 (23%), cardiac transplantation in 18 (17%), and clinical decomp

190 Liver transplantation immediately preceded cardiac transplantation in 2 of the 27 cases because of

191 lymphatic flow index following heterotrophic cardiac transplantation in a murine model of chronic rej

192 of the systemic right ventricle necessitates cardiac transplantation in a subset of patients.

193 t common form of cardiomyopathy and cause of cardiac transplantation in children.

194 test this concept, 20 subjects who underwent cardiac transplantation in infancy and healthy age-match

195 al issues relating to the use of heterotopic cardiac transplantation in infants and the capacity of t

196 For cardiac transplantation in infants, T cells are depleted

197 However, when antibodies are low, in cardiac transplantation in neonates for example, no dese

198 alovirus (CMV) replication is frequent after cardiac transplantation in recipients with pretransplant

199 Heterotopic cardiac transplantation in the intra-abdominal position

200 of 14 mg x kg(-1) x min(-1) for referral for cardiac transplantation in these patients requires reeva

201 hepatic associations and the role for early cardiac transplantation in this population is critical.

202 Using a mouse model of cardiac transplantation in which donor-specific toleranc

203 used complementary murine models of skin and cardiac transplantation in which prolonged allograft acc

204 one of the indicators used to optimally time cardiac transplantation in women.

205 is a leading cause of heart failure (HF) and cardiac transplantations in Western countries.

206 ent mice had exaggerated immune responses to cardiac transplantation, including increased numbers of

207 ses in a non-BCR-transgenic model of C57BL/6 cardiac transplantation into BALB/c recipients treated w

208 Cardiac transplantation is a life-saving procedure in in

209 Cardiac transplantation is also discussed.

210 Cardiac transplantation is an accepted therapy for patie

211 Cardiac transplantation is an effective therapy for end-

212 Cardiac transplantation is an excellent treatment for en

213 CMV replication after cardiac transplantation is associated with chronic endot

214 nical donation after circulatory death (DCD) cardiac transplantation is being implemented with increa

215 nagement, especially for individuals in whom cardiac transplantation is indicated.

216 Survival after cardiac transplantation is markedly reduced due to the p

217 re of the lymphatics, the function following cardiac transplantation is poorly understood.

218 Cardiac transplantation is the most effective treatment

219 If other therapies are ineffective, cardiac transplantation is the only therapeutic recourse

220 ion causes heart failure, but its role after cardiac transplantation is unclear.

221 The prognosis for patients with ACM after cardiac transplantation is unknown.

222 with the continuing organ donor shortage for cardiac transplantation, left ventricular assist devices

223 c neovascularization, we used an established cardiac transplantation model and showed that unlike wil

224 In a rat cardiac transplantation model coadministration of a none

225 Studies in a murine cardiac transplantation model demonstrated that synergis

226 The mouse heterotopic cardiac transplantation model has been used extensively

227 We show in a mouse cardiac transplantation model that antidonor immune resp

228 A murine heterotopic cardiac transplantation model was used to test whether r

229 s to transplantation tolerance using a mouse cardiac transplantation model.

230 heterotopic (abdominal) vascularized murine cardiac transplantation model.

231 ated the establishment of fully vascularized cardiac transplantation models in small mammals.

232 composite outcome (all-cause death [n=128], cardiac transplantation [n=55], or left ventricular assi

233 ntricular Assist System [LVAS] for Bridge to Cardiac Transplantation; NCT00121472).

234 lopathy Using Rituximab [Rituxan] Therapy in Cardiac Transplantation; NCT01278745).

235 sk stratification for all-cause mortality or cardiac transplantation (net reclassification improvemen

236 r or implantable cardioverter-defibrillator, cardiac transplantation, new heart failure, stroke, or o

237 Cardiac transplantation of angiogenic EOCs from healthy

238 (LVADs) are increasingly used as a bridge to cardiac transplantation or as destination therapy.

239 ve disease that resulted in the necessity of cardiac transplantation or in death.

240 time to, adverse outcome, defined as death, cardiac transplantation, or clinical decompensation requ

241 well as long-term clinical outcomes (death, cardiac transplantation, or HF hospitalization).

242 Primary end points were death, cardiac transplantation, or hospitalization.

243 outcomes: 1) the combined endpoint of death, cardiac transplantation, or ventricular assist device (V

244 its performance in predicting risk of death, cardiac transplantation, or ventricular assist device pl

245 Subjects were followed for death, cardiac transplantation, or ventricular assist device pl

246 te the increasing use of LVAD as a bridge to cardiac transplantation, our knowledge regarding its eff

247 ssociated with an increased risk of death or cardiac transplantation over a median follow-up of 2.4 y

248 29) or with increasing duration of time from cardiac transplantation (P = 0.0874).

249 sis, and readmission and reduced hazards for cardiac transplantation (P<0.05 for all).

250 safety of neostigmine and glycopyrrolate in cardiac transplantation patients.

251 DE3A DEL and had been treated with PDE3i pre-cardiac transplantation, PDE3A1 mRNA abundance and micro

252 Retrospective chart review queried cardiac transplantations performed at our institution fr

253 ssess the relationship between the volume of cardiac transplantation procedures performed in a center

254 Cardiac transplantation remains the treatment of last re

255 , volatile anesthesia and hypothermia during cardiac transplantation remains to be established.

256 than three decades of clinical experience in cardiac transplantation resulted in the spread of the pr

257 higher Index for Mortality Prediction After Cardiac Transplantation score (5 [2-7] versus 4 [1-6]; P

258 ost of the pericardial effusions occurred in cardiac transplantation, sirolimus is not approved for t

259 he areas of left ventricular assist devices, cardiac transplantation, strain-rate echocardiography, a

260 els in failing human hearts retrieved during cardiac transplantation surgery.

261 eart failure; the tissue was obtained during cardiac transplantation surgery.

262 s who eventually may require transplantation.Cardiac transplantation survival has improved, but morbi

263 alendronate or calcitriol immediately after cardiac transplantation sustained minimal bone loss duri

264 Hospitals without cardiac transplantation that serve high-acuity HF patien

265 ular recovery or as a bridge for patients to cardiac transplantation, these devices are now being use

266 plication of peak VO2 as an aid to determine cardiac transplantation timing should be re-examined.

267 ression and surgical techniques have allowed cardiac transplantation to become a viable option and th

268 es to nonhuman leukocyte antigen (HLA) after cardiac transplantation to identify antibodies associate

269 Using syngeneic cardiac transplantation to model ischemia-reperfusion in

270 ally altered mice in an established model of cardiac transplantation to study the role of MHC and co-

271 ession analyses were performed, censoring at cardiac transplantation, to assess the impact of preoper

272 oreactive T cells persist after induction of cardiac transplantation tolerance, but fail to acquire a

273 In three infants awaiting orthotopic cardiac transplantation, transplantation was successfull

274 sirolimus versus azathioprine treatment in a cardiac transplantation trial (28.6% versus 9.3%, respec

275 aque progression during the first year after cardiac transplantation (Tx) is unknown.

276 An interdisciplinary protocol for cardiac transplantation using extended-donor criteria or

277 This study investigates the outcomes of cardiac transplantation using older donors.

278 nd systemic emboli, heart failure admission, cardiac transplantation, ventricular arrhythmias, and ca

279 itigates inflammatory and immune sequelae of cardiac transplantation via the A(2B)AR.

280 The interval risk of death or/cardiac transplantation was associated with poorer ventr

281 HC class I and II mismatched murine model of cardiac transplantation was developed (bm12.Kd.IE to C57

282 Cardiac transplantation was performed in 10 patients.

283 Primary orthotopic cardiac transplantation was performed in 35 patients (me

284 primary end point of all-cause mortality or cardiac transplantation was reached by 42 of 86 patients

285 Pacing was required in 70%; cardiac transplantation was required in 4 children.

286 A murine model of cardiac transplantation was used (bm12.Kd.IE to C57BL/6)

287 EFECT (EFfect of Etanercept on Cardiac Transplantation) was a randomized, controlled, d

288 Using a murine model of MHC-mismatched cardiac transplantation, we investigated the influence o

289 Using a model of murine cardiac transplantation, we now demonstrate that allorea

290 While studying Th responses induced by cardiac transplantation, we observed that mice deficient

291 hymocyte globulin (mATG) in a mouse model of cardiac transplantation, we previously showed that perit

292 Using a mouse model of cardiac transplantation, we show that when Listeria mono

293 METHODS AND Using heterotopic rat cardiac transplantation, we tested the effects of donor

294 Overall, cardiac mortality and the need for cardiac transplantation were low (6% and 4%, respectivel

295 Durable LVAD and cardiac transplantation were performed in 11.7% as an ex

296 Patients <25 years of age, after cardiac transplantation, were enrolled (2003 to 2008) an

297 n in renal function is frequently seen after cardiac transplantation, which is partly explained by th

298 Coronary arteries from patients undergoing cardiac transplantation with CAD or without CAD were stu

299 However, BNP behaves unusually after cardiac transplantation, with a failure to return to nor

300 tients will be rehospitalized and/or require cardiac transplantation within 1 year of admission.